2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol
- CAS No.
- 1220973-37-4
- Chemical Name:
- 2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol
- Synonyms
- CPD1068;2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol;2-amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol;1,3-Propanediol, 2-amino-2-[5-[5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-benzofuranyl]-
- CBNumber:
- CB43334087
- Molecular Formula:
- C22H22ClN3O5
- Molecular Weight:
- 443.88
- MDL Number:
- MOL File:
- 1220973-37-4.mol
- MSDS File:
- SDS
2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol Properties
| Boiling point | 684.0±65.0 °C(Predicted) |
|---|---|
| Density | 1.370±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMF: 5 mg/ml; DMSO: 20 mg/ml |
| form | A crystalline solid |
| pka | 11.68±0.20(Predicted) |
| color | White to off-white |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 | |||||||||
| NFPA 704 |
|
2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol price More Price(23)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 27670 | AKP-11 ≥95% | 1220973-37-4 | 1mg | $36 | 2026-04-30 | Buy |
| Cayman Chemical | 27670 | AKP-11 ≥95% | 1220973-37-4 | 5mg | $153 | 2026-04-30 | Buy |
| Cayman Chemical | 27670 | AKP-11 ≥95% | 1220973-37-4 | 10mg | $268 | 2026-04-30 | Buy |
| Cayman Chemical | 27670 | AKP-11 ≥95% | 1220973-37-4 | 25mg | $587 | 2026-04-30 | Buy |
| Biosynth | VYB97337 | 2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol | 1220973-37-4 | 25mg | $1186.75 | 2026-06-05 | Buy |
2-Amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol Chemical Properties, Uses, Production
Uses
S1P1 Agonist 1 is a S1P1 agonist with immunomodulatory activities.
in vivo
S1P1 Agonist 1 (1.3mg/kg) attenuates EAE disease. EAE is the animal model of multiple sclerosis which is extensively used for investigating clinical studies for multiple sclerosis drugs. S1P1 Agonist 1 treatment reduces peripheral total blood lymphocyte and T lymphocyte counts significantly. The reduction in total lymphocytes and T cells are 48% and 41% in AKP-11 treated animals, respectively. The reduction in the CD4+ and CD8+ T cell populations are 41% and 40% in S1P1 Agonist 1 treated animals, respectively. S1P1 Agonist 1 treatment reduces CNS infiltration of T cells and Cytokines and enhances neuroprotection. S1P1 Agonist 1 treatment has little effect on the heart rate of animals. The decrease in blood pressure is also smaller with S1P1 Agonist 1 treatment as compared animals treated with FTY720[1].
References
[1] Samuvel DJ, et al. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis. PLoS One. 2015 Oct 29;10(10):e0141781. DOI:10.1371/journal.pone.0141781
